Amoy Diagnostics Co., Ltd. (SHE:300685)

Market Cap	8.27B -4.9%
Revenue (ttm)	1.13B -4.8%
Net Income	290.10M -7.9%
EPS	0.74 -6.5%
Shares Out	386.86M
PE Ratio	28.97
Forward PE	23.04
Dividend	0.30 (1.40%)
Ex-Dividend Date	Jun 3, 2025

Volume	5,059,399
Average Volume	8,613,285
Open	21.85
Previous Close	21.38
Day's Range	21.08 - 21.85
52-Week Range	19.27 - 27.17
Beta	0.74
RSI	41.72
Earnings Date	Apr 28, 2026

About Amoy Diagnostics

Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a comprehensive genomic profiling assay; AmoyDx BRCA Pro panel,...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2008
• Employees: 1,144
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300685

Financial Performance

In 2024, Amoy Diagnostics's revenue was 1.11 billion, an increase of 6.27% compared to the previous year's 1.04 billion. Earnings were 254.86 million, a decrease of -2.53%.